Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs

Epilepsia

Volumn 37, Issue SUPPL. 2, 1996, Pages

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Ad verse events; Anticonvulsants; Epilepsy; Interactions; Pharmacokinetics; Seizures; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TOPIRAMATE; VIGABATRIN;

ANTICONVULSANT THERAPY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; EPILEPSY; HUMAN; PRIORITY JOURNAL;

EID: 0029897629     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb06032.x     Document Type: Conference Paper

References (55)

1. Scheyer RD, Cramer JA. Pharmacokinetics of antiepileptic drugs. Semin Neurol 1990;10:414-21.
2. Cloyd J. Pharmacokinetic pitfalls of present antiepileptic medications. Epilepsia 1991;32(suppl 5):S53-65.
3. Perucca E, Pisani F. Pharmacokinetics and interactions of the new antiepileptic drugs. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs (Epilepsy Res Suppl 3). Amsterdam: Elsevier, 1991:79-88.
4. Thomson AH, Brodie MJ. Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 1992;23:216-30.
5. Schmidt B. Gabapentin. In: Levy R, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs, 3rd ed. New York: Raven Press, 1989:925-35.
6. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993;24:441-52.
7. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993:41-6.
8. Vollmer K, Anhut H, Thomann P, et al. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. In: Manelis J, Bental E, Loeber JN, Dreifuss FE, eds. The XVIIth epilepsy international symposium. New York: Raven Press, 1989:209-11 (Advances in epileptology, vol. 17).
9. Foot M, Wallace J. Gabapentin. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs (Epilepsy Res Suppl 3). Amsterdam: Elsevier, 1991:109-13.
10. Vollmer K-O, von Hodenberg A, Kölle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986;36:830-9.
11. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993;46:409-27.
12. Bartosyk GD, Meyerson W, Reimann W, et al. Gabapentin. In: Meldrum BS, Porter RJ, eds. Current problems in epilepsy 4: new anticonvulsant drugs. London: John Libby, 1986:147-68.
13. Allen E, Jawad S, Wrae S, Richens A. Does the anticonvulsant gabapentin lack enzyme inducing properties? Proceedings of the 17th International Epilepsy Congress, Jerusalem, 1987.
14. Lippert B, Metcalf BW, Jung MJ, Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyricacid aminotransferase in mammalian brain. Eur J Biochem 1977;74:441-5.
15. Schlechter PJ. Clinical pharmacology of vigabatrin. Br J Pharmacol 1989;27:19S-22S.
16. Rey E, Pons G. Olive G. Vigabatrin clinical pharmacokinetics. Clin Pharmacokinet 1992;23:267-78.
17. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986;40:581-6.
18. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37:69-74.
19. Johannessen SI. Pharmacokinetics of anti-epileptic drugs and their clearance significance. Behav Neurol 1990;3(suppl 1):1-113.
20. Kumps A, Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharmaceut Drug Disp 1990;11: 365-70.
21. Kristensen O, Klitgaard NA, Jonsson B, Sindrup S. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 1983;68:145-50.
22. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacological and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1993,43:873-88.
23. Perucca E. The clinical pharmacology of the new antiepileptic drugs. Pharmacol Res 1993;89-106.
24. 14C-oxcarbazepine in man. Xenobiotica 1986;16:769-78.
25. Anonymous. Oxcarbazepine. Lancet 1989;2:196-8.
26. Yuen AWC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988;26:242P.
27. Yau MK, Garnett WR, Wargin WA, Pellock JM. A single dose, dose proportionality and bioequivalence study of lamotrigine in normal volunteers. Epilepsia 1991;32(suppl 3):8.
28. Ramsay E, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal®) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
29. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
30. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43.
31. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-76.
32. Binnie CD, van Emde Boas W, Kasteleijin-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
33. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11: 147-50.
34. Pisani F, Xiao B, Fagio A, et al. Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994;19:245-8.
35. Leppik IE, Graves NM. Potential antiepileptic drugs. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs, 3rd ed. New York: Raven Press, 1989:983-90.
36. Wilensky AJ, Friel PN, Ojemann LM. Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia 1985;26: 602-6.
37. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993;45:1041-65.
38. Adsumalli VE, Yang YT, Wong KK, et al. Felbamate pharmacokinetics in the rat, rabbit and dog. Drug Metab Disp 1991;19:1116-25.
39. Fuerst RH, Graves NM, Leppik IE, et al. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia 1988;29:488-91.
40. Sachdeo RC, Padela MF. The effect of felbamate on phenobarbital serum concentrations. Epilepsia 1994;35(suppl 8): 94.
41. Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproate disposition. Epilepsia 1991;32:15.
42. Patrias J, Espe-Lillo J, Ritter FJ. Felbamate-methosuximide interaction. Epilepsia 1992;33(suppl 3):84.
43. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolite. Epilepsia 1991;32:130-2.
44. Maryanoff BE, Margul BL. Topiramate. Drugs Future 1989; 14:342-4.
45. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
46. Easterling DE, Zakzewski T, Moyer MD, et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988;29:662.
47. Doose DR, Gisclon LG, Stellar SM, Riffits JM, Hills JF. The effect of food on the bioavailability of topiramate from 100-and 400-mg tablets in healthy male subjects. Epilepsia 1992;33(suppl 3):105.
48. Doose DR, Scott VV, Margul BL. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988;29:662.
49. Gisclon LG, Curtin CR, Kramer LD. The steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8):54.
50. Liao S, Rosenfeld WE, Palmer M, et al. Steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy on monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8):117.
51. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nayak RK. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy or monotherapy and during combination therapy. Epilepsia 1994;35(suppl 8):54.
52. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia (in press).
53. Wu WN, Heebner JB, Streeter AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. Pharm Res 1994;11(suppl):S336.
54. Gisclon LG, Riffits JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharm Res 1993;10(suppl):S397.
55. Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia 1996;37(suppl 2):S14-17 (this issue).